Ovid Therapeutics Inc.

For the period ended Sep 30, 2026. Filed Nov 10, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 10, 2026

OVID$2.80-1.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(in thousands, except share and per share data)	For The Three Months EndedSeptember 30, 2026	For The Three Months EndedSeptember 30, 2025	For The Nine Months EndedSeptember 30, 2026	For The Nine Months EndedSeptember 30, 2025
Revenue:
License and other revenue	$—	$132	$735	$6,534
Total revenue	—	132	735	6,534
Operating expenses:
Research and development	15,695	5,870	36,833	18,993
General and administrative	6,669	6,785	19,809	17,687
Total operating expenses	22,364	12,655	56,642	36,680
Loss from operations	(22,364)	(12,523)	(55,907)	(30,146)
Other income (expense), net	1,584	365	3,130	3,069
Loss before provision for income taxes	(20,780)	(12,158)	(52,777)	(27,077)
Provision for income taxes	—	—	—	—
Net loss	$(20,780)	$(12,158)	$(52,777)	$(27,077)
Net loss per share of Series A preferred stock, basic and diluted	$—	$(168.01)	$—	$(374.3)
Weighted-average Series A preferred stock shares outstanding, basic and diluted	—	1,250	—	1,250
Net loss per share of common stock, basic and diluted	$(0.10)	$(0.17)	$(0.29)	$(0.37)
Weighted-average common stock shares outstanding, basic and diluted	203,021,564	71,114,181	178,958,195	71,090,052

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.